Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About OnKure Therapeutics, Inc.
Reneo Pharmaceuticals, Inc. is a clinical-stage company, which engages in the research and development of therapies for rare genetic mitochondrial diseases. The company is headquartered in Irvine, California and currently employs 8 full-time employees. The company went IPO on 2021-04-09. The firm is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The firm's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The firm is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).
Industry: Pharmaceutical Preparations Peers: Apexigen, Inc. Carisma Therapeutics Inc. MARIZYME, INC. HOOKIPA Pharma Inc. LUMOS PHARMA, INC. Dianthus Therapeutics, Inc. /DE/ NextCure, Inc. Spero Therapeutics, Inc. Xilio Therapeutics, Inc.
